Jennifer Bain
Neurology with Special Qualifications in Child Neurology · New York, NYNPI 1942599154
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $800 of the $1,027 with a category attached, or 77.9%. Ultragenyx Pharmaceutical Inc. accounts for 77.9% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $853, more than ten times the $16 reported in 2019. That places this record below the midpoint for neurology with special qualifications in child neurology clinicians in NY, where the typical reported total is $845.
Across 6 payments — averaging $171.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ultragenyx Pharmaceutical Inc.$800
- Acadia Pharmaceuticals Inc$125
- Neurelis, Inc.$36
- Biogen$33
- Livanova USA, Inc.$17
- Aquestive Therapeutics, Inc.$16
Across 47 payments — averaging $30,641 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$527K
- Biogen$512K
- Genentech, Inc.$274K
- Pfizer$85K
- Amgen$43K
What the payments were for
- Consulting fees$80078%
- Food & beverage$19119%
- Education$363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 1 | $800 |
| Acadia Pharmaceuticals Inc | 1 | $125 |
| Neurelis, Inc. | 1 | $36 |
| Biogen | 1 | $33 |
| Livanova USA, Inc. | 1 | $17 |
| Aquestive Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAYBUE$125
How this compares
$1,027 in reported general payments places this provider in the 50th percentile of 161 neurology with special qualifications in child neurology providers in New York.
See all neurology with special qualifications in child neurology providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate ErMethylphenidate Hcl | 13 | $952 |
| Naltrexone Hcl | 13 | $904 |
| Clonazepam | 15 | $720 |
| Zonisamide | 20 | $414 |
| Alprazolam | 11 | $267 |
| Fluoxetine Hcl | 22 | $251 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in New York
- Claudia ChiribogaNew York$220K
- Kaleb YohayNew York$125K
- Heather LauNew York$103K
- Darryl DevivoNew York$67K
- Mary Lynn ChuNew York$66K
- Gurcharanjeet KaurNew York$40K
- Jahannaz DastgirNew York$28K
- Naomi LubarrNew York$16K
- Tristan SandsNew York$12K
- Divya JayaramanNew York$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.